批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2024/10/31 |
SUPPL-31(补充) |
Approval |
REMS |
|
|
|
2018/09/18 |
SUPPL-24(补充) |
Approval |
REMS |
STANDARD
|
|
|
2014/08/04 |
SUPPL-13(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/08/15 |
SUPPL-11(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/11/29 |
SUPPL-8(补充) |
Approval |
Labeling |
|
|
|
2008/09/19 |
SUPPL-5(补充) |
Approval |
Labeling |
|
|
|
2008/02/15 |
SUPPL-4(补充) |
Approval |
Labeling |
|
|
|
2007/10/25 |
SUPPL-3(补充) |
Approval |
Labeling |
|
|
|
2002/04/22 |
ORIG-1(原始申请) |
Approval |
|
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
无 |
与本品治疗等效的药品
活性成分:ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE 剂型/给药途径:CAPSULE;ORAL 规格:325MG;50MG;40MG;30MG 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020232 |
001 |
NDA |
FIORICET W/ CODEINE |
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE |
CAPSULE;ORAL |
325MG;50MG;40MG;30MG |
Prescription |
Yes |
Yes |
AB |
1992/07/30
|
ACTAVIS LABS UT INC |
075929 |
001 |
ANDA |
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE |
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE |
CAPSULE;ORAL |
325MG;50MG;40MG;30MG |
Discontinued |
No |
No |
AB |
2002/04/22
|
NOSTRUM LABS INC |
076560 |
001 |
ANDA |
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE |
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE |
CAPSULE;ORAL |
325MG;50MG;40MG;30MG |
Prescription |
No |
No |
AB |
2004/06/10
|
LGM PHARMA |
204649 |
001 |
ANDA |
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE |
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE |
CAPSULE;ORAL |
325MG;50MG;40MG;30MG |
Prescription |
No |
No |
AB |
2020/07/08
|
STRIDES PHARMA |
215138 |
001 |
ANDA |
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE |
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE |
CAPSULE;ORAL |
325MG;50MG;40MG;30MG |
Prescription |
No |
No |
AB |
2022/01/26
|
HIKMA |